Cover Image
市場調查報告書

PharmaPoint:大腸躁鬱症 (IBS) - 美國的醫藥品市場2023年為止的預測與市場分析

PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325949
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:大腸躁鬱症 (IBS) - 美國的醫藥品市場2023年為止的預測與市場分析 PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 116 Pages
簡介

大腸躁鬱症 (IBS)是常見的障礙,關係到腸道機能的變化,特徵是腹部的不適感。IBS雖然不是生死攸關的疾,但會強烈影響患者的生活品質 (QOL) 。

本報告提供美國大腸躁鬱症 (IBS) 治療藥之市場相關調查分析,提供您疾病概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 分類
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 疾病的管理

  • 診斷和治療概要
  • 美國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌
  • 其他藥效分類

第6章 未滿足需求和機會

  • 概要
  • 更有效的藥物療法
  • IBS D類型的治療方法
  • IBS M類型的治療方法
  • 解決腹痛和飽脹感症狀的治療方法
  • 提高IBS的診斷率

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 產品簡介:後期開發平台 (IBS D)
  • 產品簡介:後期開發平台 (IBS C)
  • 其他

第8章 市場預測

  • 美國

第9章 附錄

圖表

目錄
Product Code: GDHC270CFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

GlobalData estimated that prescription drug sales for IBS in the US were approximately $480.1m in 2013. The key growth drivers for the IBS market in the US are the anticipated increasing uptake of Ironwood/Actavis/Almirall/Astellas' Linzess, the potential label expansion of Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan for IBS-D, the potential introduction of four additional therapies, and the increasing prevalent cases of IBS during the forecast period.

Scope

  • Overview of Irritable Bowel Syndrome including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Irritable Bowel Syndrome market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Irritable Bowel Syndrome
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in the US

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. US

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands, IBS-C
    • 5.2.1. Amitiza (lubiprostone)
    • 5.2.2. Linzess (linaclotide)
  • 5.3. Product Profiles - Major Brands, IBS-D
    • 5.3.1. Lotronex (alosetron)
  • 5.4. Product Profiles - Major Brands, Other
    • 5.4.1. Antidepressants
  • 5.5. Other Therapeutic Classes

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies for the IBS-D Subtype
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Therapies for the IBS-M Subtype
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Therapies to Address Abdominal Pain and Bloating Symptoms
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Diagnosis Rate for IBS
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
  • 7.3. Product Profiles - Late-Stage Pipeline, IBS-D
    • 7.3.1. Eluxadoline
    • 7.3.2. Ibodutant (MEN-15596)
    • 7.3.3. Xifaxan (rifaximin)
  • 7.4. Product Profiles - Late-Stage Pipeline, IBS-C
    • 7.4.1. Plecanatide
    • 7.4.2. Tenapanor (AZD1722, RDX5791)
  • 7.5. Other Drugs in Development for IBS

8. Market Outlook

  • 8.1. US
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Drivers and Barriers - US

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed IBS Patients
    • 9.4.2. Drugs Included in Each Therapy Type
    • 9.4.3. Launch and Patent Expiry Dates
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the US Market, 2014†
  • Table 5: IBS Diagnosis and Treatment Country Profile - US
  • Table 6: Leading Branded Treatments for IBS, 2014
  • Table 7: Product Profile - Amitiza
  • Table 8: Safety of Amitiza - Most Frequently Reported Adverse Events
  • Table 9: Amitiza SWOT Analysis, 2014
  • Table 10: Product Profile - Linzess
  • Table 11: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks
  • Table 12: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks
  • Table 13: Safety of Linzess - Most Frequently Reported Adverse Events
  • Table 14: Linzess SWOT Analysis, 2014
  • Table 15: Product Profile - Lotronex
  • Table 16: Safety of Lotronex - Most Frequently Reported Adverse Events
  • Table 17: Lotronex SWOT Analysis, 2014
  • Table 18: Use of Antidepressants in IBS, SWOT Analysis, 2014
  • Table 19: Summary of Other Therapeutic Classes of Pharmacologics in IBS, 2014
  • Table 20: Unmet Needs and Opportunities in IBS
  • Table 21: Drugs in Late-Stage Clinical Development for IBS, 2014
  • Table 22: Product Profile - Eluxadoline
  • Table 23: Eluxadoline SWOT Analysis, 2014
  • Table 24: Product Profile - Ibodutant
  • Table 25: Ibodutant SWOT Analysis, 2014
  • Table 26: Product Profile - Xifaxan
  • Table 27: Safety of Xifaxan - Most Frequently Reported Adverse Events
  • Table 28: Xifaxan SWOT Analysis, 2014
  • Table 29: Product Profile - Plecanatide
  • Table 30: Plecanatide SWOT Analysis, 2014
  • Table 31: Product Profile - Tenapanor
  • Table 32: Tenapanor SWOT Analysis, 2014
  • Table 33: Drugs in Early-Stage Clinical Development for IBS, 2014
  • Table 34: Sales Forecasts ($m) for IBS in the US, 2013-2023
  • Table 35: Key Events Impacting Sales for IBS in the US, 2013-2023
  • Table 36: Global IBS Market - Drivers and Barriers, 2013-2023
  • Table 37: IBS Market in the US - Drivers and Barriers, 2013-2023
  • Table 38: Key Launch Dates
  • Table 39: Key Patent Expiries
  • Table 40: High-Prescribing Physicians (Non-KOLs) Surveyed, in the US

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
  • Figure 2: IBS - Phase IIb-III Pipeline, October 2014
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
  • Figure 4: Clinical and Commercial Positioning of Eluxadoline
  • Figure 5: Clinical and Commercial Positioning of Ibodutant
  • Figure 6: Clinical and Commercial Positioning of Xifaxan
  • Figure 7: Clinical and Commercial Positioning of Plecanatide
  • Figure 8: Clinical and Commercial Positioning of Tenapanor
  • Figure 9: Sales for IBS in the US by Therapy Type, 2013-2023
Back to Top